Literature DB >> 24087840

Avascular necrosis of femoral head as the initial manifestation of CML.

Suresh Kumar1, Deepak Bansal, Mahesh Prakash, Prashant Sharma.   

Abstract

A 12-year-old female is reported who presented with right hip pain for 6 months. With massive splenohepatomegaly and leukocytosis, CML was suspected and confirmed on bone-marrow examination and cytogenetics. Further investigations confirmed avascular necrosis (AVN) of the right femoral head. CML was treated by hydroxyurea, followed by imatinib. AVN was managed conservatively; patient demonstrated progressive improvement, though a mild limp in the gait was persisting at 22 months. AVN as the initial manifestation of CML is a rarity. Leukostasis is considered to be the pathophysiological mechanism. In view of the rarity, a case is reported, along with compilation of previously reported cases.

Entities:  

Keywords:  MRI; acute lymphoblastic leukemia; bone scan; chronic myeloid leukemia; hyperviscosity; osteonecrosis

Mesh:

Year:  2013        PMID: 24087840     DOI: 10.3109/08880018.2013.831961

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Nilotinib induced avascular necrosis of femoral head in an adult chronic myeloid leukemia patient.

Authors:  Shinto Francis Thekkudan; Soniya Nityanand
Journal:  J Clin Orthop Trauma       Date:  2017-11-24

2.  Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia.

Authors:  Mohamed A Yassin; Abbas H Moustafa; Abdulqadir J Nashwan; Ashraf T Soliman; Hatim El Derhoubi; Shehab F Mohamed; Deena S Mudawi; Sarah ELkourashy; Deena-Raiza Asaari; Hope-Love G Gutierrez; Radwa M Hussein; Mohamed Al Musharraf; Samah Kohla; Ahmed Elsayed; Nader Al-Dewik
Journal:  Clin Med Insights Blood Disord       Date:  2015-07-23

3.  Avascular necrosis in patients with chronic myeloid leukemia: A systematic review.

Authors:  Mohamed Yassin; Abdulrahman F Al-Mashdali; Husam N Al-Dubai
Journal:  Acta Biomed       Date:  2022-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.